NEW YORK--(BUSINESS WIRE)--Samsung BioLogics (KRX:207940), a leading biopharmaceutical cGMP manufacturing company based in South Korea, is pleased to announce that it has been recognized as a CMO Leadership Awards winner presented by Life Science Leader magazine for the fourth consecutive year since 2013.
The company won awards in all of the six core categories this year: the overall quality, reliability, capabilities, expertise, compatibility, and development.
“Each year, the CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Executive Editor, Life Science Leader magazine and OutsourcedPharma.com. “Recipients are evaluated by the executives and managers at the sponsors the CMOs have worked, in the 6 critical categories of capabilities, compatibility, expertise, quality, reliability and development. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries.”
The CMO leadership Awards are determined through an industry research conducted by Industry Standard Research (ISR). More than 80 contract manufacturers around the world were assessed by 30 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey to determine winners in the six categories. The survey questioned those from pharmaceutical and biopharmaceutical companies of all sizes and were screened for decision-making related to working with contract manufacturing suppliers. They were asked questions about their perception of suppliers.
“Industry Standard Research is honored to conduct the research for Life Science Leader’s CMO Awards. ISR’s stringent screening processes and the high caliber of qualification required to provide experiential feedback on their involvement with contract suppliers over the past 18 months. This enables users of ISR’s research to make confident business decisions based on the experiences of their industry peers.” Andrew Schafer, President of Industry Standard Research.
"Samsung BioLogics is honored to once again receive the CMO Leadership Award, which recognizes contract manufacturing organizations of the highest quality. Being recognized in all core criteria – development, quality, expertise, reliability, capabilities, and comparability – attests to our solid position as a full service provider for mammalian biopharmaceutical products, being responsible for clinical development and commercial manufacturing at our state-of-the-art facilities,” said TH Kim, CEO of Samsung BioLogics. “We have recently completed a successful IPO, and we'll continue to provide quality-driven cGMP manufacturing for flexible and cost-effective services that ensure dedicated support for our clients and their patients.”
Samsung BioLogics aims to strengthen its presence in the rapidly growing global biopharmaceutical market by utilizing its world-class plant design and operation technology that maximizes production efficiency and ensures highest quality products for the patient.
Samsung BioLogics is investing about USD 730 million in its third plant with a bioreactor capacity of 180,000 liters.
Once the third plant is operational in 2018, Samsung BioLogics is expected to have the world’s largest capacity for a biologics CMO, with a total production capacity of 362,000 liters.
Currently, Samsung BioLogics has the production capacity of 182,000 liters: the first plant with 30,000 liters of capacity started full commercial operation in November 2015, and the second plant with 152,000 liters of capacity started operation in February 2016.